Table of Contents
ISRN Hematology
Volume 2011, Article ID 473152, 4 pages
Case Report

Iron Depletion: An Ameliorating Factor for Sickle Cell Disease?

1Hemoglobinopathies Laboratory, Department of Human and Clinical Genetics, Leiden University Medical Center, Einthovenweg 20, 2300RC Leiden, The Netherlands
2Department of Clinical Chemistry, Westeinde Hospital, Lijnbaan 32, 2512 VA, The Hague, The Netherlands

Received 10 March 2011; Accepted 28 April 2011

Academic Editors: H. Knecht, C. Martinez, and F. Oberg

Copyright © 2011 P. C. Giordano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. R. Serjeant, “One hundred years of sickle cell disease,” British Journal of Haematology, vol. 151, no. 5, pp. 425–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. P. C. Giordano, “Prospective and retrospective primary prevention of Hemoglobinopathies in multiethnic societies,” Clinical Biochemistry, vol. 42, no. 18, pp. 1757–1766, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. B. C. Kar, “Clinical profile of sickle cell trait,” Journal of Association of Physicians of India, vol. 50, no. 11, pp. 1368–1371, 2002. View at Google Scholar · View at Scopus
  4. J. A. Little, V. R. McGowan, G. J. Kato et al., “Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review,” Haematologica, vol. 91, no. 8, pp. 1076–1083, 2006. View at Google Scholar · View at Scopus
  5. M. Yavarian, M. Karimi, E. Bakker, C. L. Harteveld, and P. C. Giordano, “Response to hydroxyurea treatment in Iranian transfusion-dependent β-thalassemia patients,” Haematologica, vol. 89, no. 10, pp. 1172–1178, 2004. View at Google Scholar · View at Scopus
  6. V. Guida, M. P. Cappabianca, A. Colosimo, F. Rafanelli, A. Amato, and B. Dallapiccola, “Influence of (G)gamma Eth158 CT and beta- (AT)x(T)y globin gene polymorphisms on HbF levels in Italian beta-thalassemia carriers and wild-type subjects,” Haematologica, vol. 91, no. 9, pp. 1275–1276, 2006. View at Google Scholar
  7. M. Brun, S. Bourdoulous, P. O. Couraud, J. Elion, R. Krishnamoorthy, and C. Lapoumeroulie, “Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells,” Pharmacogenomics Journal, vol. 3, no. 4, pp. 215–226, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. F. M. Gill, L. A. Sleeper, S. J. Weiner et al., “Clinical events in the first decade in a cohort of infants with sickle cell disease,” Blood, vol. 86, no. 2, pp. 776–783, 1995. View at Google Scholar · View at Scopus
  9. R. Fodde, M. Losekoot, M. H. Van den Broek et al., “Prevalence and molecular heterogeneity of alpha+ thalassemia in two tribal populations from Andhra Pradesh, India,” Human Genetics, vol. 80, no. 2, pp. 157–160, 1988. View at Google Scholar · View at Scopus
  10. J. L. Kerkhoffs, C. L. Harteveld, P. Wijermans et al., “Very mild pathology in a case of Hb S/β0-thalassemia in combination with a homozygosity for the α-thalassemia 3.7 kb deletion,” Hemoglobin, vol. 24, no. 3, pp. 259–263, 2000. View at Google Scholar · View at Scopus
  11. V. Berdoukas and J. Wood, “In search of the optimal iron chelation therapy for patients with thalassemia major,” Haematologica, vol. 96, no. 1, pp. 5–8, 2011. View at Google Scholar